OmniAb SPAC Presentation Deck

ADDING A LEADING DRUG DISCOVERY PLATFORM TO AVISTA'S PHARMA SERVICES PORTFOLIO I Discovery OmniAb AVISTA CAPITAL PARTNERS Built capabilities and competitive strengths to become partner of choice BI designed to yield industry's most diverse sets of high-quality antibodies Rapid deep sequencing of immune repertoires Differentiated ion channel capabilities Diversified business model Robust IP portfolio Early-Stage Research & Development BioReliance charles river eMolecules inc Research FOCUS MPIⓇ Diagnostics RESEARCH AVISTA CAPITAL PARTNERS Track record of creating value through: Investing to add new capabilities and accelerate revenue growth Late-Stage Development & Commercialization ( Margin expansion Accretive M&A to enhance scale and capabilities Creative financings Syneos Health Avista investment professionals have deep domain expertise in the pharma services sector Eight completed investments, including five successful exits via IPOs and sales to strategic acquirors Avista professionals' investment experience spans the full spectrum of drug development including drug discovery, preclinical / bio-analytical testing and late stage / post-approval SUBC 5 OmniAb

View entire presentation